Background: This review provides a comprehensive summary of the production of 177 Lu to
meet expected future research and clinical demands. Availability of options represents the …

In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased.
Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases …

Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …

Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options …

The purpose of the EANM Dosimetry Committee is to provide recommendations and
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …

Purpose: Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-
growing tumors, which frequently express somatostatin receptors on their cell membranes …

This article is the result of the North American Neuroendocrine Tumor Society consensus
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …

Purpose Fibroblast activation protein (FAP), which has high expression in cancer-associated
fibroblasts of epithelial cancers, can be used as a theranostic target. Our previous study …

The purpose of these guidelines is to assist physicians caring for patients with
neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide …

Purpose Peptide receptor radionuclide therapy (PRRT) with 90 Y and 177 Lu provides
objective responses in neuroendocrine tumours, and is well tolerated with moderate toxicity …